These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 22916600)

  • 1. [CROI 2012: updates on raltegravir].
    MMW Fortschr Med; 2012 May; 154 Suppl 1():41. PubMed ID: 22916600
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.
    Vispo E; Mena A; Maida I; Blanco F; Cordoba M; Labarga P; Rodriguez-Novoa S; Alvarez E; Jimenez-Nacher I; Soriano V
    J Antimicrob Chemother; 2010 Mar; 65(3):543-7. PubMed ID: 20032006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA notifications. FDA grants approval for raltegravir.
    AIDS Alert; 2009 Apr; 24(4):46-8. PubMed ID: 19382366
    [No Abstract]   [Full Text] [Related]  

  • 4. Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C.
    Macías J; Neukam K; Portilla J; Iribarren JA; de Los Santos I; Rivero A; Márquez M; Delgado M; Téllez F; Merino D; Giner L; von Wichmann MA; Pineda JA;
    J Antimicrob Chemother; 2011 Jun; 66(6):1346-50. PubMed ID: 21398295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Integrase inhibition].
    Bogner JR
    MMW Fortschr Med; 2009 Apr; 151(18):68-71. PubMed ID: 19769082
    [No Abstract]   [Full Text] [Related]  

  • 6. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA notifications. FDA approves raltegravir for HIV-1 treatment-naive patients.
    AIDS Alert; 2009 Sep; 24(9):106-7. PubMed ID: 19938313
    [No Abstract]   [Full Text] [Related]  

  • 8. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New therapeutic strategies for raltegravir.
    Garrido C; Soriano V; de Mendoza C
    J Antimicrob Chemother; 2010 Feb; 65(2):218-23. PubMed ID: 20016017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.
    Burger DM
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1151-60. PubMed ID: 20701552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient.
    Di Biagio A; Rosso R; Siccardi M; D'Avolio A; Bonora S; Viscoli C
    J Antimicrob Chemother; 2009 Oct; 64(4):874-5. PubMed ID: 19643773
    [No Abstract]   [Full Text] [Related]  

  • 12. Raltegravir: the first HIV type 1 integrase inhibitor.
    Hicks C; Gulick RM
    Clin Infect Dis; 2009 Apr; 48(7):931-9. PubMed ID: 19231980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Select updates from the 16th CROI: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use.
    Boyle BA; Cohen CJ; DeJesus E; Elion R; Frank I; Moyle GJ; Sax PE
    AIDS Read; 2009 Apr; 19(4):158-60. PubMed ID: 19388184
    [No Abstract]   [Full Text] [Related]  

  • 14. Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.
    Nguyen BY; Isaacs RD; Teppler H; Leavitt RY; Sklar P; Iwamoto M; Wenning LA; Miller MD; Chen J; Kemp R; Xu W; Fromtling RA; Vacca JP; Young SD; Rowley M; Lower MW; Gottesdiener KM; Hazuda DJ
    Ann N Y Acad Sci; 2011 Mar; 1222():83-9. PubMed ID: 21434946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Integrase inhibition--a new mode of action in HIV therapy].
    van Lunzen J; Degen O
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():64-7. PubMed ID: 19031567
    [No Abstract]   [Full Text] [Related]  

  • 16. [Long-term therapy strategy with raltegravir. Appropriate in all illness phases].
    Warpakowski A
    MMW Fortschr Med; 2011 May; 153(18):50-1. PubMed ID: 21604599
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of chronic hepatitis B].
    Mauss S
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():48-51. PubMed ID: 19031564
    [No Abstract]   [Full Text] [Related]  

  • 18. Role of raltegravir in HIV-1 management.
    Rokas KE; Bookstaver PB; Shamroe CL; Sutton SS; Millisor VE; Bryant JE; Weissman SB
    Ann Pharmacother; 2012 Apr; 46(4):578-89. PubMed ID: 22496475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of chronic hepatitis C in patients with HIV coinfection: efficacy and tolerance].
    Pol S
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B264-73. PubMed ID: 12180300
    [No Abstract]   [Full Text] [Related]  

  • 20. Anti-HIV agents. Atazanavir and raltegravir--an interesting combination.
    TreatmentUpdate; 2009; 21(3):3-4. PubMed ID: 19623725
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.